This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study
Julia Dixon-Douglas, et al.. The Lancet Oncology, 2026.
DOI: 10.1016/S1470-2045(26)00339-6
-
Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial
Luis Lara Gonzalez, et al.. The Lancet Oncology, 2026.
DOI: 10.1016/S1470-2045(26)00247-0
-
Healthcare organizations can now connect EHR and additional industry data to ChatGPT
Weekly News Brief: September 8–11, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of September 8–11, 2026.
This week’s brief covers two analyses of AI-based tumor-infiltrating lymphocyte scoring in early-stage breast cancer and an AI connection to electronic health records so patient records can be queried through ChatGPT for Healthcare..
To learn more about computational TIL assessments, read "Two Studies Evaluate AI-Based TIL Scoring for Breast Cancer Prognostication," or see the source reports in The Lancet Oncology (CATALINA, APHINITY).
For more information on Epic and ChatGPT, read "New EHR Connection Allows Clinicians to Query Patient Charts Through ChatGPT for Healthcare," or see the announcement.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.